Bringing innovation to global health

Crucell’s research efforts currently focus on developing vaccines and proteins that address unmet market needs. The discovery, development and manufacture of next-generation medical products is facilitated by our  range of innovative technologies.

Cutting-edge technologies

Crucell’s strong research and development (R&D) pipeline is supported through a range of patented technologies. Our technologies open up new areas of research, speed our development programs and optimize production processes. Crucell continues to extend the applications of existing technologies.

From discovery to market

Our current R&D pipeline includes the following product areas:

 

Vaccines:

• Classical vaccines: Many viruses have been shown to grow extremely well on Crucell's PER.C6^® cells under controlled and scalable conditions. These viruses can then be inactivated, purified and marketed as inactivated whole virus (also called 'whole-killed'), split or subunit vaccines.
• Recombinant vaccines: Our adenovirus-based AdVac^® vectors can be used to create recombinant (engineered) vaccines by inserting a small piece of genetic material from the disease causing virus into a harmless adenoviral vector that acts as a 'vehicle'. The recombinant vaccine triggers an immune response  against this specific virus in vaccinated individuals, so that they are protected from a later attach by the disease-causing virus. The AdVac^®-based vaccine can be manufactured to large-scale commercial volumes on the PER.C6^® human cell line.

 

Proteins:

• Recombinant proteins: Recombinant proteins, such as blood factors, can be produced efficiently and safely on the PER.C6^® human cell line.

• Antibodies: MAbstract^® technology is used to identify strong binding and neutralizing antibodies for specific disease targets. Antibodies discovered in this way can then be produced using PER.C6^® technology.

  

Learn more about Crucell’s development programs

Quick Links

• Products
• Partners
• Technologies